C4 Therapeutics Inc (CCCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2019 | |
| Sales | 5,364 |
| Gross Profit | 5,364 |
| Operating Expenses | 15,365 |
| Operating Income | -10,001 |
| Interest Expense | -558 |
| Other Income | -1 |
| Pre-tax Income | -9,444 |
| Income Tax | 650 |
| Net Income Continuous | -10,094 |
| Net Income | $-10,094 |
| EPS Basic Total Ops | -8.93 |
| EPS Basic Continuous Ops | -7.34 |
| EPS Diluted Total Ops | -8.93 |
| EPS Diluted Continuous Ops | -7.34 |
| EBITDA(a) | $-10,001 |